Expression of key oestrogen-regulated genes differs substantially across the menstrual cycle in oestrogen receptor-positive primary breast cancer

Breast Cancer Research and Treatment

Volumn 138, Issue 1, 2013, Pages 157-165

  Haynes, Ben P ^a   Viale, Giuseppe ^c,d   Galimberti, Viviana ^d   Rotmensz, Nicole ^d   Gibelli, Bianca ^d   A'Hern, Roger ^b   Smith, Ian E ^a   Dowsett, Mitch ^a,b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF MILAN   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Estradiol; Menstrual cycle; Oestrogen receptor; Oestrogen regulated; Premenopausal; Progesterone receptor

Indexed keywords

ESTROGEN RECEPTOR; PARAFFIN; PROGESTERONE; PROGESTERONE RECEPTOR; RNA;

ADULT; ARTICLE; BREAST CANCER; CDC20 GENE; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION REGULATION; GREB1 GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MKI67 GENE; OVARY CYCLE; PDZK1 GENE; PREMENOPAUSE; PRIMARY TUMOR; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROGESTERONE RECEPTOR GENE; TEF1 GENE; TOP2A GENE;

EID: 84874646443     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2426-0     Document Type: Article

References (29)

1. Clark GM, Osborne CK, McGuire WL (1984) Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 2:1102-1109
2. Pujol P, Daures JP, Thezenas S, Guilleux F, Rouanet P, Grenier J (1998) Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause. Cancer 83:698-705
3. Smith I, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer J-U, Ashley SE, Francis S, Boeddinghaus I, Walsh G, IMPACT Trialists Group (2005) Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, Tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen or combined with tamoxifen (IMPACT) multicentre double-blind randomized trial. J Clin Oncol 23:5108-5116
4. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A'Hern R, Salter J, Detre S, Hills M, Walsh G (2007) Prognostic value of Ki67 Expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Ca Inst 99:167-170
5. Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M (2008) Outcome prediction for estrogen receptor-positive breast cancer based on post-neoadjuvant endocrine tumour characteristics. J Natl Ca Inst 100:1380-1388
6. Freedman OC, Amir E, Hanna W, Kahn H, O'Malley F, Dranitsaris G, Cole DE, Verma S, Folkerd E, Dowsett M, Clemons M (2010) A randomized trail exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer. Breast Cancer Res Treat 119:155-161
7. Klijn JG, Beex LV, Mauriac L, van Zijl JA, Veyret C, Wildiers J, Jassem J, Piccart M, Burghouts J, Becquart D, Seynaeve C, Mignolet F, Duchateau L (2000) Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst 92:903-911
8. Jannuzzo MG, Di Salle E, Spinelli R, Pirotta N, Buchan P, Bello A (2009) Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone. Breast Cancer Res Treat 11:491-499
9. Khan SA, Gonchoroff NJ, Miller LE (1997) Expression of pS2, c-erbB-2, and cathepsin D during the menstrual cycle in human breast cancers. Ann Surg Oncol 4:462-469
10. Mangia A, De Lena M, Barletta A, Marzullo F, Attolico M, Stea B, Petroni S, Labriola A, Cellamare G, Digiesi G, Altieri R, Schittulli F, Paradiso AJ (1998) Timing of breast cancer surgery within the menstrual cycle: tumor proliferative activity, receptor status and short-term clinical outcome. J Exp Clin Cancer Res 17:317-323
11. Coradini D, Veneroni S, Pellizzaro C, Daidone MG (2003) Fluctuation of intratumor biological variables as a function of menstrual timing of surgery for breast cancer in premenopausal patients. Ann Oncol 14:962-964
12. Vasei M, Azarpira N, Talei A (2006) Status of estrogen and progesterone receptors in various phases of the menstrual cycle in breast cancer. Arch Iran Med 9:250-253
13. Atalay C, Kanliöz M, Altinok M (2002) Menstrual cycle and hormone receptor status in breast cancer patients. Neoplasma 49:278
14. Pujol P, Daures JP, Brouillet JP, Chang S, Rouanet P, Bringer J, Grenier J, Maudelonde T (2001) A prospective prognostic study of the hormonal milieu at the time of surgery in premenopausal breast carcinoma. Cancer 91:1854-1861
15. Saad Z, Bramwell VH, Wilson SM, O'Malley FP, Jeacock J, Chambers AF (1998) Expression of genes that contribute to proliferative and metastatic ability in breast cancer resected during various menstrual phases. Lancet 351:1170-1173
16. Grant CS, Ingle JN, Suman VJ, Dumesic DA, Wickerham DL, Gelber RD, Flynn PJ, Weir LM, Intra M, Jones WO, Perez EA, Hartmann LC (2009) Menstrual cycle and surgical treatment of breast cancer: findings from the NCCTG N9431 study. J Clin Oncol 27:3620-3626
17. Thorpe H, Brown SR, Sainsbury JR, Perren TJ, Hiley V, Dowsett M, Nejim A, Brown JM (2008) Timing of breast cancer surgery in relation to menstrual cycle phase: no effect on 3-year prognosis: the ITS Study. Br J Cancer 98:39-44
18. Dunbier AK, Anderson H, Ghazoui Z, Folkerd EJ, A'hern R, Crowder RJ, Hoog J, Smith IE, Osin P, Nerurkar A, Parker JS, Perou CM, Ellis MJ, Dowsett M (2010) Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women. J Clin Oncol 28:1161-1167
19. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826
20. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009
21. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160-1167
22. Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, Zabaglo L, Mallon E, Green AR, Ellis IO, Howell A, Buzdar AU, Forbes JF (2011) Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J Clin Oncol 29:4273-4278
23. Zurrida S, Galimberti V, Gibelli B, Luini A, Gianoglio S, Sandri MT, Passerini R, Maisonneuve P, Zucali P, Jeronesi G, Pigatto F, Veronesi U (2001) Timing of breast cancer surgery in relation to the menstrual cycle: an update of developments. Crit Rev Oncol Hematol 38:223-230
24. Regan MM, Viale G, Mastropasqua MG, Maiorano E, Golouh R, Carbone A, Brown B, Suurküla M, Langman G, Mazzucchelli L, Braye S, Grigolato P, Gelber RD, Castiglione-Gertsch M, Price KN, Coates AS, Goldhirsch A, Gusterson B (2006) International breast cancer study group: re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst 98:1571-1581
25. Viale G, Regan MM, Mastropasqua MG, Maffini F, Maiorano E, Colleoni M, Price KN, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Gusterson BA, Castiglione-Gertsch M, Gelber RD, Goldhirsch A, Coates AS (2008) International breast cancer study group: predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst 100:207-212
26. Dunbier AK, Ghazoui Z, Anderson H, Smith IE, Dowsett M (2010) Molecular profiling of aromatase inhibitor-treated post-menopausal breast tumours identifies determinants of response [abstract]. Cancer Res 70(Suppl 2):S2-S5
27. Dowsett M, Attree SL, Virdee SS, Jeffcoate SL (1985) Oestrogen-related changes in sex hormone binding globulin levels during normal and gonadotrophin-stimulated menstrual cycles. Clin Endocrinol 23:303-312
28. Plymate SR, Moore DE, Cheng CY, Bardin CW, Southworth MB, Levinski MJ (1985) Sex hormone-binding globulin changes during the menstrual cycle. J Clin Endocrinol Metab 61:993-996
29. Stricker R, Eberhart R, Chevailler MC, Quinn FA, Bischof P, Stricker R (2006) Establishment of detailed reference values for luteinizing hormone, follicle stimulating hormone, estradiol, and progesterone during different phases of the menstrual cycle on the Abbott ARCHITECT analyzer. Clin Chem Lab Med 44:883-887